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A b s t r a c t
Background: Recently, it has been suggested that the type of stent used in primary percutaneous coronary interventions (pPCI) 
might impact upon the outcomes of patients with acute myocardial infarction (AMI). Indeed, drug-eluting stents (DES) reduce 
neointimal hyperplasia compared to bare-metal stents (BMS). Moreover, the later generation DES, due to its biocompatible 
polymer coatings and stent design, allows for greater deliverability, improved endothelial healing and therefore less restenosis 
and thrombus generation. However, data on the safety and performance of DES in large cohorts of AMI is still limited. 
Aim: To compare the early outcome of DES vs. BMS in AMI patients.
Methods: This was a prospective, multicentre analysis containing patients from 64 hospitals in Switzerland with AMI undergoing 
pPCI between 2005 and 2013. The primary endpoint was in-hospital all-cause death, whereas the secondary endpoint included 
a composite measure of major adverse cardiac and cerebrovascular events (MACCE) of death, reinfarction, and cerebrovascular event.
Results: Of 20,464 patients with a primary diagnosis of AMI and enrolled to the AMIS Plus registry, 15,026 were referred for 
pPCI and 13,442 received stent implantation. 10,094 patients were implanted with DES and 2,260 with BMS. The overall 
in-hospital mortality was significantly lower in patients with DES compared to those with BMS implantation (2.6% vs. 7.1%, 
p < 0.001). The overall in-hospital MACCE after DES was similarly lower compared to BMS (3.5% vs. 7.6%, p < 0.001). After 
adjusting for all confounding covariables, DES remained an independent predictor for lower in-hospital mortality (OR 0.51, 
95% CI 0.40–0.67, p < 0.001). Since groups differed as regards to baseline characteristics and pharmacological treatment, 
we performed a propensity score matching (PSM) to limit potential biases. Even after the PSM, DES implantation remained 
independently associated with a reduced risk of in-hospital mortality (adjusted OR 0.54, 95% CI 0.39–0.76, p < 0.001).
Conclusions: In unselected patients from a nationwide, real-world cohort, we found DES, compared to BMS, was associated 
with lower in-hospital mortality and MACCE. The identification of optimal treatment strategies of patients with AMI needs 
further randomised evaluation; however, our findings suggest a potential benefit with DES.
Key words: acute myocardial infarction, drug-eluting stents, bare-metal stents
Kardiol Pol 2014; 72, 4: 315–323
Address for correspondence:  
Prof. Paul Erne, AMIS Plus Data Centre, Institute of Social and Preventive Medicine, University of Zurich, Switzerland, e-mail: paul.erne@erne-net.ch 
Received: 04.06.2013 Accepted: 10.09.2013 Available as AoP: 27.11.2013
Copyright © Polskie Towarzystwo Kardiologiczne
www.kardiologiapolska.pl
Milosz Jaguszewski et al.
316
INTRODUCTION
Primary percutaneous coronary intervention (pPCI) with 
stent implantation is acknowledged as the optimal treatment 
strategy in patients with acute myocardial infarction (AMI) 
[1]. Primary PCI with bare metal stent (BMS) implantation 
has been associated with a significant improvement in clini-
cal outcome and therefore has become standard practice [1]. 
The introduction of drug-eluting stents (DES) has emerged as 
a rational pPCI alternative in this particular setting of AMI [2]. 
Recently, it has been suggested that the type of stent 
used in pPCI might impact upon the outcomes of patients 
with AMI [3]. Indeed, DES has been confirmed as reduc-
ing neointimal hyperplasia and persistent fibrin deposition 
compared to BMS [4]. Moreover, the later generation DES, 
due to its biocompatible polymer coatings and stent design, 
allows for greater deliverability, improved endothelial healing 
and therefore less restenosis and reinfarction [5]. However, 
concerns have been raised with regard to the safety of DES, 
particularly in the AMI setting [5–7]. In the recently published 
COMFORTABLE AMI Trial, a comparison of new-generation 
biolimus-eluting stents (BES) and BMS resulted in a reduction 
of a composite of major adverse cardiovascular events among 
patients with ST-segment-elevation myocardial infarction 
(STEMI) undergoing pPCI [8]. However, randomised clinical 
trials (RCTs) did not confirm the benefit of DES as regards 
the mortality rate [9]. Due to the conflicting reports regard-
ing the hard outcomes after DES vs. BMS implantation, the 
most accurate treatment strategy of pPCI during AMI is still 
the subject of debate.
In this context, we performed a post hoc analysis from 
a prospective, multicentre cohort to investigate whether DES 
compared to BMS influences early outcomes in the setting 
of AMI. The presented all-comer observation addresses the 
real-world setting and therefore reflects the care of patients 
in routine clinical practice. 
METHODS
Study design and population
The Acute Myocardial Infarction in Switzerland (AMIS) Plus 
project was launched in January 1997 as a large, nationwide 
prospective registry of patients admitted with acute coronary 
syndrome (ACS) to 82 hospitals in Switzerland, including 
STEMI, non-STEMI (NSTEMI) and unstable angina (Fig. 1). 
The registry is officially supported by the Swiss Societies of 
Cardiology, Internal Medicine and Intensive Care Medicine. 
The design of the registry has been previously described 
[10, 11]. All participating centres, ranging from community 
institutions to large tertiary facilities, provide blinded data, 
being subsequently centralised at the AMIS Plus Data Cen-
tre. All data provided through an internet or paper-based 
questionnaire was subsequently checked for plausibility and 
consistency in the Institute of Social and Preventive Medicine 
at the University of Zurich, Switzerland. The registry was ap-
proved by the Over-Regional Ethics Committee for Clinical 
Figure 1. All hospitals which have participated in the AMIS project (blue colour — currently participating hospitals)
www.kardiologiapolska.pl
DES compared to BMS improve short-term survival in patients with AMI undergoing primary PCI
317
Statistical analysis
The results are presented as percentages for categorical varia-
bles and analysed using the non-parametric Pearson c2 test 
or Fisher’s exact test as appropriate. Continuous variables 
are expressed as means ± standard deviation (SD) and com-
pared using the Student’s unpaired t-test for normal distribu-
tion and continuous non-normally distributed variables are 
expressed as median and interquartile ranges and analysed 
using the Mann-Whitney U test. To examine predictors for 
in-hospital mortality, multivariate logistic regression was 
used and included the following variables: stent type (BMS 
or DES), multi-vessel revascularisation, age, gender, LM in-
volvement, Killip class > 2, Charlson comorbidities weighted 
index > 2 and out-of-hospital resuscitation. To limit the ob-
servational character of the study, we performed a propensity 
score matching to create matched DES (n = 2,137) and BMS 
(n = 2,137) cohorts. Optimal matching was obtained using 
a logistic regression model with stent type used as dependent 
variable. Independent variables were age, gender, resuscita-
tion before admission, STEMI, Killip class > 2, Charlson 
comorbidity score ≥ 2 and MVD. All statistical tests were 
two-tailed. P-value of < 0.05 was considered statistically 
significant. SPSS software (version 19, SPSS Inc, Chicago, IL, 
USA) was used for all statistical analyses.
Studies, the Swiss Board for Data Security, and all cantonal 
Ethics Commissions.
Data extraction
The AMIS Plus Central Database collects 230 items includ-
ing medical history, co-morbidities, known cardiovascular 
risk factors (dyslipidaemia, arterial hypertension, diabetes, 
obesity and smoking), clinical presentation, out-of-hospital 
management, early in-hospital management, reperfusion 
therapy, hospital course, diagnostic tests used or planned, 
length of stay, discharge medication and discharge destina-
tion, immediate drug treatment and discharge medication. 
The non-cardiovascular co-morbidities were assessed using 
the Charlson index [12]. Patients were enrolled in the registry 
based on their final diagnosis. 
Patient selection
Between January 2005 and March 2013, 20,464 patients with 
AMI (STEMI and NSTEMI) were enrolled to the AMIS Plus regi-
stry. 17,651 underwent any pPCI. Of these, 15,026 underwent 
pPCI and 13,442 pPCI with stent implantation. 10,094 patients 
were implanted with DES and 2,260 with BMS. 942 patients 
were excluded from the final analysis due to lack of data re-
garding the stent type. 146 patients received variable absorb-
able scaffolds. The study flow chart is presented in Figure 2. 
Definitions
STEMI was defined by characteristic symptoms with electro-
cardiographic (ECG) changes and cardiac marker elevation 
(creatine kinase MB fraction at least twice the upper limit of 
normal or troponin I or T above individual hospital cut-off le-
vels for MI). All patients required ST-segment elevation and/or 
a new development of left bundle branch block (LBBB) on the 
initial ECG at presentation. NSTEMI was defined as cardiac 
marker elevation with no ST-elevation in admission ECG. 
Reinfarction was defined as clinical signs or symptoms of 
ischaemia with ECG changes indicative of new ischaemia (new 
ST-changes or new LBBB) and a re-rise of biomarkers follow-
ing the initial infarction. A cerebrovascular event was defined 
as any event due to ischaemic, thrombotic or haemorrhagic 
disturbances confirmed by a neurologist or imaging modality.
Multivessel disease (MVD) was defined as a presence of an-
giographic stenosis of  ≥ 50% in at least two main epicardial coro-
nary arteries and/or involving the left main (LM) when a surgical 
bypass graft was concerned. The decision regarding single-vessel 
PCI (S-PCI) or multivessel PCI (M-PCI) attempt and DES or BMS 
implantation was performed at the physician’s discretion.
Study endpoints
The primary endpoint of the study was in-hospital all-cause 
mortality. Secondary endpoints included a composite endpoint 
of major adverse cardiac and cerebrovascular events (MACCE) 
including death, reinfarction and/or cerebrovascular event.
Figure 2. Study flow chart; AMI — acute myocardial in-
farction; BMS — bare-metal stent; DES — drug-eluting stent; 
PCI — percutaneous coronary intervention 
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RESULTS
Study population and baseline
Of the included 12,354 patients undergoing the pPCI and 
stent implantation during AMI between 2005 and 2013, we 
identified 10,094 (82%) patients with DES and 2,260 (18%) 
patients with BMS implantation (Fig. 2). Baseline charac-
teristics, stratified by stent use, are shown in Table 1. No 
differences were documented in terms of door-to-balloon 
time (DES vs. BMS: 67 min; interquartile range [IQR] 25– 
–153 vs. 65 min; IQR 25–135, p = 0.22), and pre-hospital 
delay (DES vs. BMS: 195 min; IQR 105–490 vs. 180 min; 
IQR 99–450, p = 0.082). In general, rates of BMS implan-
tation were greater among sicker patients with a history of 
out-of-hospital reanimation, Killip class III/IV, cerebrovascu-
lar disease, renal disease, cancer, and Charlson weighted 
index ≥ 2. A DES was more likely used in patients with LM 
stenosis and MVD. In addition, immediate drug therapy with 
acetylsalicylic acid, glycoprotein IIb/IIIa inhibitors, beta-block-
ers and angiotensin-converting-enzyme inhibitors/angiotensin 
II receptor antagonists and statins were more prevalent in pa-
tients treated with BMS. In contrast, vasopressors were more 
frequently used among patients receiving DES compared to 
BMS. No difference was noted in terms of P2Y12 blockers 
use between the two groups (Table 2). 
In-hospital outcomes and predictors of mortality
Overall, in-hospital mortality after DES implantation was lower 
compared to BMS (2.6% vs. 7.1%, p < 0.001), as was MACCE 
(3.5% vs. 7.6%, p < 0.001, Table 3). 
After adjusting for all different covariables, a DES re-
mained a positive independent predictor of survival (odds 
ratio [OR] 0.51, 95% confidence interval [CI] 0.40–0.67, 
p < 0.001, Table 4). In multivariable regression, STEMI, MVD, 
LM lesion, age, Charlson weighted index ≥ 2, out-of-hospital 
cardiac arrest and Killip III/IV were also identified as predictors 
of in-hospital mortality (Table 4). No differences were noted in 
the rate of reinfarction and cerebrovascular events (Table 3). 
An additional analysis regarding the cardiogenic shock after 
the pPCI and bleeding rate did not show any differences 
between the two groups receiving DES or BMS (Table 3).
Table 1. Baseline characteristics of AMI patients who underwent primary percutaneous coronary intervention according to type 
of stent 
Variable Bare-metal stent Drug-eluting stent P
Number of patients 2,260 10,094
Gender, male 1,716/2,260 (75.9) 7,857/10,094 (77.8) 0.051
Age [years] 65.0 ± 13.2 62.3 ± 12.1 < 0.001
Pre-hospital delay [min]; min, median, IQR 180 (99, 450) 195 (105, 490) 0.082
Resuscitation prior to admission 220/2,259 (9.7) 572/10,094 (5.7) < 0.001
Killip classes 3/4 239/2,235 (10.7) 550/10,058 (5.5) < 0.001
ST-segment elevation MI 1,736/2,260 (76.8) 7,155/10,094 (70.9) < 0.001
Family history 537/1,796 (29.9) 3,081/8,730 (35.3) < 0.001
Current smoker 810/1,857 (43.6) 3,861/8,481 (45.5) 0.14
Dyslipidaemia 983/1,929 (51.0) 4,644/8,921 (52.1) 0.39
Hypertension 1,179/2,084 (56.6) 5,280/9,511 (55.5) 0.38
Obesity (BMI > 30)  366/1,808 (20.2) 1,697/7,995 (21.1) 0.37
Diabetes 328/2,104 (15.6) 1,570/9,650 (16.3) 0.45
Coronary artery disease 525/2,205 (23.8) 2,883/9,968 (28.9) < 0.001
Past history of AMI 202/2,166 (9.3) 1,260/9,862 (12.8) < 0.001
Heart failure 34/2,164 (1.6) 149/9,856 (1.5) 0.85
Cerebrovascular disease 105/2,164 (4.9) 309/9,856 (3.1) < 0.001
Renal disease (moderate to severe) 102/2,164 (4.7) 338/9,856 (3.4) 0.005
Cancer diseases 127/2,164 (5.9) 387/9,856 (3.9) < 0.001
Charlson score ≥ 2 337/2,164 (17.4) 1,438/9,856 (14.6) 0.001
Left main 67/2,253 (3.0) 479/10,055 (4.8) < 0.001
Multivessel disease 1,235/2,255 (54.8) 5,921/10,057 (58.9) < 0.001
Door-to-balloon time [min]; min, median, IQR 65 (25, 135) 67 (25, 153) 0.22
Data are presented as numbers (percentages) or mean ± standard deviation or median with interquartile range; AMI — acute MI; BMI — body 
mass index; IQR — interquartile range; MI — myocardial infarction
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Propensity score matching  
(2,137 DES vs. 2,137 BMS)
Even after propensity score matching, significant reductions in 
mortality rate and overall MACCE were noted in patients receiv-
ing DES compared to BMS (3.8% vs. 5.8%, p = 0.004; 4.8% 
vs. 6.4%, p = 0.033, respectively). DES implantation remained 
independently associated with a reduced risk of in-hospital 
mortality (adjusted OR 0.54, 95% CI 0.39–0.76, p < 0.001). 
DISCUSSION
Our results suggest that DES is beneficial compared to BMS 
regarding in-hospital mortality and overall MACCE. This 
observational analysis includes a real-world population and 
therefore reflects routine clinical practice.
DES has been proven more effective than BMS in pre-
venting the need for repeat revascularisation [13–15]. The 
restenosis rate of nearly 20% to 30% within 6–9 months 
Table 2. Immediate drug therapy 
Variable Bare-metal stent Drug-eluting stent P 
Number of patients 2,260 10,094
Acetylsalicylic acid 2,191/2,253 (97.2) 9,899/10,074 (98.3) 0.002
P2Y12 blocker* 2,151/2,251 (95.6) 9,638/10,067 (95.7) 0.69
Glycoprotein IIb/IIIa 696/2,204 (31.6) 3,437/9,947 (34.6) 0.008
Vasopressors 321/2,201 (14.6) 828/9,905 (8.4) 0.001
Beta-blocker 1,176/2,218 (53.0) 6,385/10,003 (63.8) 0.001
ACEI/AT 1,177/2,221 (53.0) 6,089/10,021 (60.8) < 0.001
Statin 1,700/2,232 (76.2) 8,264/10,028 (82.4) < 0.001
Data are presented as numbers (percentages); *Clopidogrel, or prasugrel or ticagrelor; ACEI — angiotensin-converting-enzyme inhibitor;  
AT — angiotensin II receptor antagonists 
Table 3. In-hospital complications and outcome of acute myocardial infarction, who underwent primary percutaneous coronary 
intervention according to type of stent 
Bare-metal stent Drug-eluting stent P 
Number of patients 2,260 10,094
Complication:
Cardiogenic shock 110/2,260 (4.9) 280/10,063 (2.8) < 0.001
Cerebrovasular event 9/2,260 (0.4) 54/10,063 (0.5) 0.51
Bleeding 81/2,260 (3.6) 311/10,063 (3.1) 0.23
Re-infarction 13/2,260 (0.6) 79/10,063 (0.8) 0.34
Mortality 160/2,260 (7.1) 263/10,094 (2.6) < 0.001
Major adverse cardiac and cerebrovascular event 165/2,157 (7.6) 321/9,232 (3.5) < 0.001
Data are presented as numbers (percentages)
Table 4. Independent predictors of in-hospital mortality
Variable Odds ratio 95% CI P
DES vs. BMS 0.52 0.40–0.68 < 0.001
ST-segment elevation MI 1.43 1.06–1.91 0.018
Multivessel disease 1.39 1.06–1.81 0.017
Left main 1.89 1.27–2.81 0.002
Female gender 1.00 0.75–1.32 0.99
Age (per additional year) 1.05 1.04–1.06 < 0.001
Charlson weighted index ≥ 2 2.23 1.71–2.92 < 0.001
Resuscitation prior to admission 5.91 4.37–7.99 < 0.001
Killip class > 2 11.6 8.84–15.1 < 0.001
BMS — bare-metal stent; CI — confidence interval; DES — drug-eluting stent; MI — myocardial infarction
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after BMS implantation has often been called the Achilles 
heel of pPCI [16]. The introduction of DES correlated with 
reduced angiographic restenosis and ischaemia-driven target 
vessel revascularisation rates has substantially strengthened 
the efforts to improve the success rate over the last decades 
[17, 18]. Restenosis remains the healing response to wire-, 
balloon- and stent-induced injury and comprises neointimal 
hyperplasia and vessel remodelling. Although the reduction 
of restenosis rate relates rather to mid-term follow-up, the 
immediate release of drugs (80–90% eluted within 30 days) 
can rapidly reduce late loss by targeting cell cycle division 
also early after stent implantation [19]. However, despite the 
reduction in reintervention rates, no robust clinically relevant 
differences up to five-year follow-up have been convincingly 
identified [16]. The results abstracted from RCTs revealed 
no significant differences as regards long-term rates of death 
or MI after DES or BMS use for both off-label and on-label 
indications [17, 20, 21]. However, the RCTs were primarily 
limited by population-size. Only the observational studies, 
with greater numbers of patients, have presented DES use as 
a better treatment strategy compared to BMS associated with 
reduced death and MI [20]. Importantly, the recently pub-
lished RCTs suggest that the new-generation DES may provide 
superior clinical outcomes to first-generation DES in patients 
with coronary artery disease and in real-world practice [22, 
23]. The differences are driven in part by in-hospital MI and 
early in-stent thrombosis [24]. 
A major matter of debate is DES implantation during the 
pPCI in patients with AMI [16]. Our analysis, based on an 
unselected AMI subset and reflecting the real-world popula-
tion, documented an improved adverse outcome measure 
and all-cause death with a similar rate of reinfarction. Some 
previous studies have been similarly in favour of DES (i.e. 
TYPHOON, HORIZONS-AMI, PASEO, and ZEST-AMI), 
whereas others have presented opposite results [7, 16, 25, 
26]. In the PASEO study, sirolimus-eluting stents (SES) and 
paclitaxel-eluting stents were documented to be safe and ef-
fective compared to BMS, with similar overall mortality [27]. 
Mauri et al. [28] in their propensity-score-matched group 
documented that risk-adjusted mortality rates and repeat 
revascularisation were lower for DES than for BMS among all 
patients with AMI, including both STEMI and NSTEMI, STEMI 
alone, and NSTEMI alone. Reinfarction was reduced after 
DES implantation compared to BMS in the NSTEMI subset 
[28]. On the other hand, the PASSION trial did not reveal any 
benefit after DES implantation compared to BMS in terms of 
clinical outcomes after one- and five-year observations [29, 
30]. Kaltoft et al. [7] reported 12 deaths before discharge 
and four classified as probable stent thrombosis in patients 
implanted with DES, and four deaths after BMS implantation 
including only one possible in-stent thrombosis. The early and 
late in-stent thrombosis could be caused by e.g. local allergic 
reactions, inflammation, and delayed endothelialisation of the 
first-generation DES [31]. Meanwhile, newly-engineered DES 
have been developed with thinner-strut platforms made of 
improved alloys providing increased radial strength and radio-
pacity [5]. This may result in less vascular injury and therefore 
reduced restenosis and throbogenicity [5, 32]. The EXAMI-
NATION trial comparing everolimus-eluting stents (EES) with 
BMS in a group of STEMI did not reveal any patient-oriented 
benefit of EES use [33] as regards the risk of restenosis and 
in-stent thrombosis [33]. The recently published COMFORT-
ABLE trial presented that the newly-designed biodegradable 
polymer BES reduce adverse outcomes compared to BMS 
mostly due to a significant reduction in rates of reinfarction 
and reintervention [34]. Also, fewer cases of definite in-stent 
thrombosis were observed in the group of BES compared to 
BMS, although the difference was not significant [34]. The 
use of biodegradable polymers in newly-engineered DES of-
fers early protection against in-stent thrombosis avoiding its 
very late proinflammatory and prothrombotic effect [32, 35]. 
Therefore, concerns regarding the late safety issue with DES 
are rather related to early-designed DES [8, 36]. New DES 
have replaced the early-generation DES in clinical practice, 
and, what is more, the old-fashioned SES such as CYPHER are 
no longer manufactured [5]. Nowadays, use of DES in AMI 
has a class IIA recommendation if patients are able to comply 
with a prolonged regimen of dual antiplatelet therapy [16].
Limitations of the study
The major limitation of the presented study is its observational 
nature with potential for selection bias and residual confound-
ing. Thus, patients with AMI who receive DES may be less ill 
than those who receive BMS; our analysis attempted to adjust 
for these differences to the extent that was possible. Second, 
the study was underpowered to reveal late in-stent thrombosis 
which remains the major limitation of early-generation DES. 
Third, the use of stent type was at the discretion of the opera-
tor and no data regarding the use of thrombectomy is avail-
able. The number of stents was not systematically recorded 
and therefore an additional analysis of cases with mixed stents 
was not possible. Moreover, our database did not allow us 
to distinguish the particular stent type implanted; therefore, 
other aspects of the stent design (e.g. strut size and thickness, 
stent material, drug or polymer) and its influence on outcome 
remains unknown. The present analysis addresses, however, 
all consecutive patients referred for urgent pPCI due to ACS 
and reflects real-world practice. Moreover, since our patients 
were not randomly assigned, we performed a propensity score 
matching to limit the potential biases.
CONCLUSIONS
The use of DES in patients with AMI undergoing pPCI ap-
pears to be associated with improved mortality and over-
all in-hospital adverse outcomes compared to BMS. The 
promising results of the present analysis warrant discussion, 
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and therefore call for an extended follow-up and perhaps 
larger randomised controlled trials to examine this strategy 
in real-world populations. 
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Stenty uwalniające leki w porównaniu ze stentami 
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S t r e s z c z e n i e
Wstęp: W kontekście ostatnio opublikowanych wyników badań typ stentu stosowanego podczas pierwotnej przezskórnej interwencji 
wieńcowej (pPCI) może istotnie wpływać na rokowanie pacjentów z ostrym zawałem serca (AMI). Stenty uwalniające leki (DES) 
w porównaniu ze stentami metalowymi (BMS) redukują hiperplazję neointimy. Ponadto DES nowej generacji, poprzez zwiększoną 
biokompatybilność pokryć polimerowych i zmienioną konstrukcję, pozwalają na lepszą dostarczalność i szybsze gojenie się śród-
błonka, zmniejszając dzięki temu liczbę restenoz i przypadków zakrzepicy w stencie. Istotnym problemem jest jednak ograniczona 
liczba badań kohortowych dotyczących bezpieczeństwa i skuteczności DES w AMI.
Cel: Celem niniejszej pracy było porównanie w obserwacji wewnątrzszpitalnej rokowania pacjentów z AMI poddanych pPCI oraz 
implantacji DES w porównaniu z BMS. 
Metody: W wieloośrodkowym prospektywnym badaniu analizie poddano pacjentów z AMI, leczonych pPCI w 64 szpitalach 
w Szwajcarii w latach 2005–2013. Ocenianym pierwszorzędowym punktem końcowym był zgon w obserwacji wewnątrzszpitalnej. 
Drugorzędowy złożony punkt końcowy obejmował poważne zdarzenia sercowo-naczyniowe i naczyniowo-mózgowe (MACCE), 
tj. zgon, ponowny zawał serca oraz incydent naczyniowo-mózgowy.
Wyniki: Spośród 20 464 pacjentów włączonych do rejestru zawałów serca w Szwajcarii (AMIS Plus registry) z rozpoznaniem AMI 
15 026 poddano pPCI, w tym u 13 442 implantowano stenty. U 10 094 osób wszczepiono DES, u 2260 — BMS. Całkowita śmier-
telność wewnątrzszpitalna była istotnie statystycznie niższa w grupie pacjentów po implantacji DES w porównaniu z chorymi, którym 
wszczepiono BMS (2,6% vs. 7,1%; p < 0,001). Częstość występowania złożonego punktu końcowego była również istotnie statystycznie 
niższa po wszczepieniu DES w porównaniu z BMS (3,5% vs. 7,6%; p < 0,001). Ponadto implantacja DES okazała się niezależnym 
czynnikiem predykcyjnym zgonu wewnątrzszpitalnego (OR 0,51; 95% CI 0,40–0,67; p < 0,001). W celu zmniejszenia różnic w far-
makoterapii oraz w charakterystyce ogólnej pacjentów zastosowano metodę propensity score matching (PSM). Po dopasowaniu grup 
metodą PSM częstość występowania pierwszorzędowego punktu końcowego była nadal istotnie statystycznie niższa po implantacji 
DES w porównaniu z BMS (adjusted OR 0,54; 95% CI 0,39–0,76; p < 0,001). Podobnie, po zastosowaniu PSM, obecność DES pozo-
stawała niezależnym czynnikiem redukującym ryzyko zgonu wewnątrzszpitalnego (adjusted OR 0,54; 95% CI 0,39–0,76; p < 0,001).
Wnioski: W niewyselekcjonowanej grupie pacjentów z AMI wszczepienie DES podczas pPCI w porównaniu z BMS powodowało 
redukcję liczby zgonów i MACCE w obserwacji wewnątrzszpitalnej. Identyfikacja najbardziej optymalnej strategii terapeutycznej 
podczas pPCI w grupie pacjentów z AMI wymaga potwierdzenia w badaniach randomizowanych, jednak wyniki niniejszego badania 
sugerują potencjalną korzyść z implantacji DES u pacjentów z AMI.
Słowa kluczowe: ostry zawał serca, stenty uwalniające leki, stenty metalowe 
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